



## Inozyme Pharma to Present at Upcoming Investor Conferences

November 11, 2021

BOSTON, Nov. 11, 2021 (GLOBE NEWSWIRE) -- [Inozyme Pharma, Inc.](#) (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases of abnormal mineralization, today announced Axel Bolte, MSc, MBA, the company's co-founder, president, and chief executive officer, will participate in the following virtual investor conferences:

- The 2021 Jefferies London Virtual Healthcare Conference. The presentation will be available on-demand beginning at 3:00 a.m. ET/8:00 a.m. GMT on Thursday, November 18, 2021.
- The Piper Sandler 33<sup>rd</sup> Annual Virtual Healthcare Conference. The fireside chat will be available on-demand beginning at 10:00 a.m. ET on Monday, November 22, 2021.

A replay of the pre-recorded presentations can be accessed from the [Investor & News](#) section of Inozyme's website under [events](#) and will be available for up to 60 days following the events.

### About Inozyme Pharma

Inozyme Pharma, Inc. (Nasdaq: INZY) is a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue, and skeleton. Through our in-depth understanding of the biological pathways involved in mineralization, we are pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. It is well established that two genes, *ENPP1* and *ABCC6*, play key roles in a critical mineralization pathway and that defects in these genes lead to abnormal mineralization. We are initially focused on developing a novel therapy, INZ-701, to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies.

Inozyme Pharma was founded in 2017 by Joseph Schlessinger, Ph.D., Demetrios Braddock, M.D., Ph.D., and Axel Bolte, MSc, MBA, with technology developed by Dr. Braddock and licensed from Yale University. For more information, please visit [www.inozyme.com](http://www.inozyme.com).

### Contacts

Investors:

Inozyme Pharma

Stefan Riley, Director of Investor Relations

[stefan.riley@inozyme.com](mailto:stefan.riley@inozyme.com)

Media:

SmithSolve

Matt Pera

973-886-9150

[matt.pera@smithsolve.com](mailto:matt.pera@smithsolve.com)